GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viridian Therapeutics Inc (STU:1S1) » Definitions » Total Debt per Share

Viridian Therapeutics (STU:1S1) Total Debt per Share : €0.25 (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Viridian Therapeutics Total Debt per Share?

€0.25 (As of Dec. 2024)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Viridian Therapeutics's Total Debt Per Share for the quarter that ended in Dec. 2024 was €0.25.

Viridian Therapeutics Total Debt per Share Historical Data

The historical data trend for Viridian Therapeutics's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viridian Therapeutics Total Debt per Share Chart

Viridian Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.09 0.02 0.12 0.36 0.25

Viridian Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.36 0.30 0.31 0.24 0.25

Viridian Therapeutics Total Debt per Share Calculation

Viridian Therapeutics's Total Debt Per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(19.66+0.49)/80.99
=0.25

Viridian Therapeutics's Total Debt Per Share for the quarter that ended in Dec. 2024 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(19.66+0.49)/80.99
=0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viridian Therapeutics Total Debt per Share Related Terms

Thank you for viewing the detailed overview of Viridian Therapeutics's Total Debt per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Viridian Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viridian Therapeutics Inc (STU:1S1) » Definitions » Total Debt per Share
Comparable Companies
AUPH NVAX INVA SNDX IOVA WVE ADPT MDXG ETNB LQDA VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
VRDN:USA 0K1R:UK
Address
221 Crescent Street, Suite 103A, Waltham, MA, USA, 02453
Website
https://www.viridiantherapeutics.com
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Viridian Therapeutics Headlines

No Headlines